ABSTRACT
Immunological tests for diagonizing tumors were based upon a coagula tion test for immunocomplex (IC). Coagulating I & C diminishes the specificity of these tests. Ishii et al. (OTSUKA PHARMACEUTICAL CO., LTD. (124)) seek to overcome this drawback by testing for com plement-binding ICs wherein the consistuent antigens are tumor associ ated antigens (tumor markers) such as BFP (basic fetoprotein), AFP (a-fetoprotein) TAG (tumor associated glycolinkage). Such an IC as bound to an insolubilized anti-complement, can be specifically bound to a labeled substance or such an IC alone can be specifically insolubilized and labeled.
